Trevi Therapeutics is planning to launch two new clinical trials this fall to test Haduvio (nalbuphine extended-release tablets) for chronic cough in people with idiopathic pulmonary fibrosis (IPF). One of the trials will be a Phase 2b study to identify the best dose of the medication for…
Trevi to launch Phase 2 trials to test Haduvio for IPF-related cough
Bexotegrast, an oral anti-fibrotic treatment candidate from Pliant Therapeutics, is being assessed in a Phase 2b clinical trial in people with idiopathic pulmonary fibrosis (IPF). Called BEACON-IPF, it intends to recruit about 270 patients at clinical sites around the globe. Details on site locations and when recruitment will start…
Some of the most important interactions in our professional lives do not occur at work, at the boardroom table, or even in an office. Often, they occur during brief introductions or chance meetings. The challenge for business leaders regardless of industry is how to briefly explain to someone what they…
Suppressing the production of a protein called NPAS2Â eased signs of lung scarring (fibrosis) in a mouse model of idiopathic pulmonary fibrosis (IPF), a new study showed. The NPAS2 gene, which codes for NPAS2, also was found to be more active in the lungs of IPF patients than in those…
Treatment with mesenchymal stem cells (MSCs) bound to tiny vesicles loaded with Ofev’s active ingredient reduced lung inflammation and scarring while  promoting lung tissue repair in a mouse model of pulmonary fibrosis (PF), a study has shown. This combination strategy worked better than Ofev alone in both young…
Note: This column describes the author’s own experiences with Dupixent (dupilumab). Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. Idiopathic pulmonary fibrosis (IPF) is progressive, which means this lung disease inevitably worsens, making it increasingly difficult for patients to…
The idiopathic pulmonary fibrosis (IPF) journey is, if nothing else, full of surprises. Some of those surprises come in the form of comorbidities, which could be a result of age, a suppressed immune system, or simply luck of the draw. The comorbidities we face are as unique as we…
Long-term exposure to even low levels of sulfur dioxide (SO2), an air pollutant with a strong odor, may place people at a higher risk of developing idiopathic pulmonary fibrosis (IPF), a study in over 400,000 U.K. residents found. The association’s strength grew as genetic susceptibility to the disease and…
The U.S. Food and Drug Administration (FDA) has agreed to review an application seeking the approval of Ofev (nintedanib) for children ages 6 to 17 with fibrosing interstitial lung diseases (ILDs). If approved, Ofev would become the first and only therapy available to treat children with fibrosing ILDs, according…
When is a larger number the better choice? It depends. Recently, I’ve noticed some people in the pulmonary fibrosis (PF) community embracing numbers in studies without understanding their context. In terms of dollars, bigger numbers are better if you’re talking about savings, but smaller numbers are better if you’re…
